TCR1020-CD8 T Cells in KRAS-mutated Cancers

NCT06707896 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Administrative decision

Conditions

Metastatic Pancreatic Adenocarcinoma
Colorectal Cancer

Interventions

DRUG: TCR1020-CD8 T cells

Sponsor

University of Pennsylvania

Collaborators

[object Object]
[object Object]